Bayer's Eylea declines by 24%, bearing the brunt of biosmilar competition

After staving off significant sales declines for Eylea, Bayer is getting hit with full force by biosimilar competition for the eye disease treatment, which saw a 24% sales decline in the first quarter.

Nội dung đang được cập nhật.